Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 31;5(11):148.
doi: 10.3390/children5110148.

Novel Therapies for Relapsed and Refractory Neuroblastoma

Peter E Zage  1   2
Affiliations
Review

Novel Therapies for Relapsed and Refractory Neuroblastoma

Peter E Zage. Children (Basel). .

Abstract

While recent increases in our understanding of the biology of neuroblastoma have allowed for more precise risk stratification and improved outcomes for many patients, children with high-risk neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances in our understanding of neuroblastoma pathogenesis, the outcomes for children with relapsed neuroblastoma remain poor. These children with relapsed neuroblastoma, therefore, continue to need novel treatment strategies based on a better understanding of neuroblastoma biology to improve outcomes. The discovery of new tumor targets and the development of novel antibody- and cell-mediated immunotherapy agents have led to a large number of clinical trials for children with relapsed neuroblastoma, and additional clinical trials using molecular and genetic tumor profiling to target tumor-specific aberrations are ongoing. Combinations of these new therapeutic modalities with current treatment regimens will likely be needed to improve the outcomes of children with relapsed and refractory neuroblastoma.

Keywords: ALK; MIBG; RET; neuroblastoma; personalized treatment; recurrent neuroblastoma; refractory neuroblastoma; relapsed neuroblastoma; retinoic acid.

PubMed Disclaimer

Conflict of interest statement

The author receives research funding from Bayer, MetronomX, and Exelixis. The funders had no role in the writing of the manuscript or in the decision to publish the manuscript.

References

    1. Cole K.A., Maris J.M. New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome. Clin. Cancer Res. 2012;18:2423–2428. doi: 10.1158/1078-0432.CCR-11-1409. - DOI - PMC - PubMed
    1. Moreno L., Rubie H., Varo A., Le Deley M.C., Amoroso L., Chevance A., Garaventa A., Gambart M., Bautista F., Valteau-Couanet D., et al. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr. Blood Cancer. 2017;64:25–31. doi: 10.1002/pbc.26192. - DOI - PubMed
    1. London W.B., Castel V., Monclair T., Ambros P.F., Pearson A.D.J., Cohn S.L., Berthold F., Nakagawara A., Ladenstein R.L., Iehara T., et al. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project. J. Clin. Oncol. 2011;29:3286–3292. doi: 10.1200/JCO.2010.34.3392. - DOI - PMC - PubMed
    1. London W.B., Bagatell R., Weigel B.J., Fox E., Guo D., Van Ryn C., Naranjo A., Park J.R. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914–4923. doi: 10.1002/cncr.30934. - DOI - PMC - PubMed
    1. Garaventa A., Parodi S., De Bernardi B., Dau D., Manzitti C., Conte M., Casale F., Viscardi E., Bianchi M., D’Angelo P., et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur. J. Cancer. 2009;45:2835–2842. doi: 10.1016/j.ejca.2009.06.010. - DOI - PubMed